- Home
- DSGN vs BDTX Comparison
DSGN vs BDTX Comparison
Compare DSGN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- BDTX
- Stock Information
- Founded
- DSGN 2017
- BDTX 2014
- Country
- DSGN United States
- BDTX United States
- Employees
- DSGN N/A
- BDTX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSGN Health Care
- BDTX Health Care
- Exchange
- DSGN Nasdaq
- BDTX Nasdaq
- Market Cap
- DSGN 208.9M
- BDTX 181.4M
- IPO Year
- DSGN 2021
- BDTX 2020
- Fundamental
- Price
- DSGN $3.87
- BDTX $2.66
- Analyst Decision
- DSGN Hold
- BDTX Strong Buy
- Analyst Count
- DSGN 1
- BDTX 6
- Target Price
- DSGN $4.00
- BDTX $14.83
- AVG Volume (30 Days)
- DSGN 92.9K
- BDTX 906.7K
- Earning Date
- DSGN 08-12-2025
- BDTX 08-05-2025
- Dividend Yield
- DSGN N/A
- BDTX N/A
- EPS Growth
- DSGN N/A
- BDTX N/A
- EPS
- DSGN N/A
- BDTX 0.09
- Revenue
- DSGN N/A
- BDTX $70,000,000.00
- Revenue This Year
- DSGN N/A
- BDTX N/A
- Revenue Next Year
- DSGN N/A
- BDTX N/A
- P/E Ratio
- DSGN N/A
- BDTX $30.14
- Revenue Growth
- DSGN N/A
- BDTX N/A
- 52 Week Low
- DSGN $2.60
- BDTX $1.20
- 52 Week High
- DSGN $7.77
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- DSGN 47.12
- BDTX 44.11
- Support Level
- DSGN $3.89
- BDTX $2.73
- Resistance Level
- DSGN $4.19
- BDTX $2.97
- Average True Range (ATR)
- DSGN 0.23
- BDTX 0.20
- MACD
- DSGN -0.02
- BDTX -0.06
- Stochastic Oscillator
- DSGN 16.18
- BDTX 2.24
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.